NCT05986682 · OUTCOME

Ophthalmology: Number of Ocular Toxicity Events Per Participant

Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma · Source last updated 2025-02-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: Events
Interval / dispersion: Full Range
Time frame: Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.

What was measured

Number of Ocular Toxicity Events (Corneal Event or Best-Corrected Visual Acuity Change) per patient, summarized by median (min, max).

Groups in this outcome

Multiple Myeloma/Blenrep Participants

Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Multiple Myeloma/Blenrep Participants	30

Reported measurements

Number of Corneal Events

Values in Events · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma/Blenrep Participants	10.5	Not reported	2	25	Not reported

Number of changes to Best-Corrected Visual Acuity

Values in Events · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma/Blenrep Participants	7	Not reported	1	25	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
2
upper Limit
25
value
10.5
title
Number of Corneal Events
categories
measurements
group Id
OG000
lower Limit
1
upper Limit
25
value
7
title
Number of changes to Best-Corrected Visual Acuity

denoms

counts
group Id
OG000
value
30
units
Participants

description

Number of Ocular Toxicity Events (Corneal Event or Best-Corrected Visual Acuity Change) per patient, summarized by median (min, max).

dispersion Type

Full Range

groups

description
Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023
id
OG000
title
Multiple Myeloma/Blenrep Participants

param Type

MEDIAN

reporting Status

POSTED

time Frame

Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.

title

Ophthalmology: Number of Ocular Toxicity Events Per Participant

type

SECONDARY

unit Of Measure

Events

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice